Publications 2024

Webster ER, Peck NE, Echeverri JD, Gholizadeh S, Tang WL, Woo R, Sharma A, Liu W, Rae CS, Sallets A, Adusumilli G, Gunasekaran K, Haabeth OAW, Leong M, Zuckermann RN, Deutsch S, McKinlay CJ (2024)
Discovery of a Peptoid-Based Nanoparticle Platform for Therapeutic mRNA Delivery via Diverse Library Clustering and Structural Parametrization
ACS Nano, 18 (33), 22181-22193
DOI 10.1021/acsnano.4c05513, PubMed 39105751

Publications 2023

Blake TR, Haabeth OAW, Sallets A, McClellan RL, Del Castillo TJ, Vilches-Moure JG, Ho WC, Wender PA, Levy R, Waymouth RM (2023)
Lysine-Derived Charge-Altering Releasable Transporters: Targeted Delivery of mRNA and siRNA to the Lungs
Bioconjug Chem (in press)
DOI 10.1021/acs.bioconjchem.3c00019, PubMed 36996808

Publications 2022

Testa S, Haabeth OAW, Blake TR, Del Castillo TJ, Czerwinski DK, Rajapaksa R, Wender PA, Waymouth RM, Levy R (2022)
Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro
Biomacromolecules, 23 (7), 2976-2988
DOI 10.1021/acs.biomac.2c00469, PubMed 35748182

Publications 2021

Haabeth OAW, Lohmeyer JJK, Sallets A, Blake TR, Sagiv-Barfi I, Czerwinski DK, McCarthy B, Powell AE, Wender PA, Waymouth RM, Levy R (2021)
An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory
bioRxiv
DOI 10.1101/2021.04.14.439891, PubMed 33880472

Haabeth OAW, Lohmeyer JJK, Sallets A, Blake TR, Sagiv-Barfi I, Czerwinski DK, McCarthy B, Powell AE, Wender PA, Waymouth RM, Levy R (2021)
An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory
ACS Cent Sci, 7 (7), 1191-1204
DOI 10.1021/acscentsci.1c00361, PubMed 34341771

Publications 2020

Frank MJ, Khodadoust MS, Czerwinski DK, Haabeth OAW, Chu MP, Miklos DB, Advani RH, Alizadeh AA, Gupta NK, Maeda LS, Reddy SA, Laport GG, Meyer EH, Negrin RS, Rezvani AR, Weng WK, Sheehan K, Faham M, Okada A, Moore AH, Phillips DL, Wapnir IL, Brody JD, Levy R (2020)
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial
J Exp Med, 217 (9)
DOI 10.1084/jem.20191712, PubMed 32558897

Haabeth OAW, Hennig K, Fauskanger M, Løset GÅ, Bogen B, Tveita A (2020)
CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages
Blood Adv, 4 (12), 2595-2605
DOI 10.1182/bloodadvances.2020001434, PubMed 32544236

Wilk AJ, Weidenbacher NL, Vergara R, Haabeth OAW, Levy R, Waymouth RM, Wender PA, Blish CA (2020)
Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy
Blood Adv, 4 (17), 4244-4255
DOI 10.1182/bloodadvances.2020002355, PubMed 32898247

Publications 2019

Benner NL, McClellan RL, Turlington CR, Haabeth OAW, Waymouth RM, Wender PA (2019)
Oligo(serine ester) Charge-Altering Releasable Transporters: Organocatalytic Ring-Opening Polymerization and their Use for in Vitro and in Vivo mRNA Delivery
J Am Chem Soc, 141 (21), 8416-8421
DOI 10.1021/jacs.9b03154, PubMed 31083999

Bogen B, Fauskanger M, Haabeth OA, Tveita A (2019)
CD4⁺ T cells indirectly kill tumor cells via induction of cytotoxic macrophages in mouse models
Cancer Immunol Immunother, 68 (11), 1865-1873
DOI 10.1007/s00262-019-02374-0, PubMed 31448380

Huszthy PC, Gopalakrishnan RP, Jacobsen JT, Haabeth OAW, Løset GÅ, Braathen R, Schenck K, Tveita AA, Munthe LA, Bogen B (2019)
B cell receptor ligation induces display of V-region peptides on MHC class II molecules to T cells
Proc Natl Acad Sci U S A, 116 (51), 25850-25859
DOI 10.1073/pnas.1902836116, PubMed 31796587

Haabeth OAW, Blake TR, McKinlay CJ, Tveita AA, Sallets A, Waymouth RM, Wender PA, Levy R (2019)
Local Delivery of Ox40l, Cd80, and Cd86 mRNA Kindles Global Anticancer Immunity
Cancer Res, 79 (7), 1624-1634
DOI 10.1158/0008-5472.CAN-18-2867, PubMed 30692215

Publications 2018

Fauskanger M, Haabeth OAW, Skjeldal FM, Bogen B, Tveita AA (2018)
Tumor Killing by CD4⁺ T Cells Is Mediated via Induction of Inducible Nitric Oxide Synthase-Dependent Macrophage Cytotoxicity
Front Immunol, 9, 1684
DOI 10.3389/fimmu.2018.01684, PubMed 30083157

Haabeth OAW, Blake TR, McKinlay CJ, Waymouth RM, Wender PA, Levy R (2018)
mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice
Proc Natl Acad Sci U S A, 115 (39), E9153-E9161
DOI 10.1073/pnas.1810002115, PubMed 30201728

Haabeth OAW, Fauskanger M, Manzke M, Lundin KU, Corthay A, Bogen B, Tveita AA (2018)
CD4⁺ T-cell-Mediated Rejection of MHC Class II-Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs
Cancer Res, 78 (16), 4573-4585
DOI 10.1158/0008-5472.CAN-17-2426, PubMed 29752262

McKinlay CJ, Benner NL, Haabeth OA, Waymouth RM, Wender PA (2018)
Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters
Proc Natl Acad Sci U S A, 115 (26), E5859-E5866
DOI 10.1073/pnas.1805358115, PubMed 29891683

Publications 2017

Khodadoust MS, Olsson N, Wagar LE, Haabeth OA, Chen B, Swaminathan K, Rawson K, Liu CL, Steiner D, Lund P, Rao S, Zhang L, Marceau C, Stehr H, Newman AM, Czerwinski DK, Carlton VE, Moorhead M, Faham M, Kohrt HE, Carette J, Green MR, Davis MM, Levy R, Elias JE et al. (2017)
Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens
Nature, 543 (7647), 723-727
DOI 10.1038/nature21433, PubMed 28329770

Matziouridou C, Rocha SDC, Haabeth OA, Rudi K, Carlsen H, Kielland A (2017)
iNOS- and NOX1-dependent ROS production maintains bacterial homeostasis in the ileum of mice
Mucosal Immunol, 11 (3), 774-784
DOI 10.1038/mi.2017.106, PubMed 29210363

Publications 2016

Lorvik KB, Hammarström C, Fauskanger M, Haabeth OA, Zangani M, Haraldsen G, Bogen B, Corthay A (2016)
Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an In Situ Inflammatory Immune Response
Cancer Res, 76 (23), 6864-6876
DOI 10.1158/0008-5472.CAN-16-1219, PubMed 27634753

Tveita A, Fauskanger M, Bogen B, Haabeth OA (2016)
Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display
Oncotarget, 7 (41), 67175-67182
DOI 10.18632/oncotarget.11946, PubMed 27626487

Publications 2015

Haabeth OA, Lorvik KB, Yagita H, Bogen B, Corthay A (2015)
Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells
Oncoimmunology, 5 (1), e1039763
DOI 10.1080/2162402X.2015.1039763, PubMed 26942052

Haabeth OA, Tveita A, Fauskanger M, Hennig K, Hofgaard PO, Bogen B (2015)
Idiotype-specific CD4(+) T cells eradicate disseminated myeloma
Leukemia, 30 (5), 1216-20
DOI 10.1038/leu.2015.278, PubMed 26449664

Tveita AA, Schjesvold F, Haabeth OA, Fauskanger M, Bogen B (2015)
Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens
Cancer Res, 75 (16), 3268-78
DOI 10.1158/0008-5472.CAN-14-3640, PubMed 26038231

Publications 2014

Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, Bogen B (2014)
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
Front Immunol, 5, 174
DOI 10.3389/fimmu.2014.00174, PubMed 24782871

Jacobsen J, Haabeth OA, Tveita AA, Schjetne KW, Munthe LA, Bogen B (2014)
Naive idiotope-specific B and T cells collaborate efficiently in the absence of dendritic cells
J Immunol, 192 (9), 4174-83
DOI 10.4049/jimmunol.1302359, PubMed 24706724

Tveita AA, Haabeth OA, Bogen B (2014)
Limitations of bystander killing in Th1/M1 immune responses against a secreted tumor antigen
Oncoimmunology, 3 (9), e954953
DOI 10.4161/21624011.2014.954953, PubMed 25941607

Tveita AA, Schjesvold FH, Sundnes O, Haabeth OA, Haraldsen G, Bogen B (2014)
Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells
Eur J Immunol, 44 (9), 2625-37
DOI 10.1002/eji.201444659, PubMed 24846412

Publications 2013

Lorvik KB, Haabeth OA, Clancy T, Bogen B, Corthay A (2013)
Molecular profiling of tumor-specific T_H1 cells activated in vivo
Oncoimmunology, 2 (5), e24383
DOI 10.4161/onci.24383, PubMed 23762808

Publications 2012

Haabeth OA, Bogen B, Corthay A (2012)
A model for cancer-suppressive inflammation
Oncoimmunology, 1 (7), 1146-1155
DOI 10.4161/onci.21542, PubMed 23170261

Publications 2011

Haabeth OA, Lorvik KB, Hammarström C, Donaldson IM, Haraldsen G, Bogen B, Corthay A (2011)
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer
Nat Commun, 2, 240
DOI 10.1038/ncomms1239, PubMed 21407206